CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

Phase 2

Completed

Conditions: Respiratory Distress Syndrome, Newborn

Interventions: Drug: CHF5633
Drug: Poractant alfa

First Posted Date: 2015-05-22

Last Posted Date: 2021-08-13

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 123

Registration Number: NCT02452476

Locations: 🇺🇸
Martha Naylor, Greenville, North Carolina, United States
🇺🇸
West Virginia University, Morgantown, West Virginia, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States

and more 20 locations

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients

Phase 4

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: ENVARSUS®
Drug: PROGRAF®
Drug: ADVAGRAF®

First Posted Date: 2015-05-04

Last Posted Date: 2018-04-13

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 428

Registration Number: NCT02432833

Locations: 🇮🇹
Chiesi farmaceutici Spa, Parma, Italy

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Multiple Ascending Dose (MAD)
Drug: Single Ascending Dose (SAD)

First Posted Date: 2015-03-12

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 48

Registration Number: NCT02386761

Locations: 🇬🇧
Quotient Clinical, Nottingham, UK, United Kingdom

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: CHF 5993 HS 200/6/25 pMDI
Drug: CHF 5993 MS 100/6/25 pMDI
Drug: CHF 5993 HS 200/6/25 pMDI + Charcoal Block
Drug: CHF 5993 MS 100/6/25 pMDI + Charcoal Block
Drug: Placebo pMDI

First Posted Date: 2015-02-10

Last Posted Date: 2021-07-02

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 50

Registration Number: NCT02359292

Locations: 🇧🇪
SGS CPU Antwerpen, Antwerpen, Belgium

Efficacy of LAMA Added to ICS in Treatment of Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: CHF 5259 12.5 µg
Drug: CHF 5259 placebo

First Posted Date: 2014-11-20

Last Posted Date: 2021-04-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 98

Registration Number: NCT02296411

Locations: 🇩🇪
Chiesi Clinical Trial Site 0202, Leipzig, Germany
🇩🇪
Chiesi Clinical Trial Site 0206, Magdeburg, Germany
🇳🇱
Chiesi Clinical Trial Site 0404, Assen, Netherlands

and more 25 locations

Drug-drug Interaction Study of CHF5993 With Cimetidine

Phase 1

Completed

Conditions: COPD

Interventions: Drug: CHF 5993 pMDI
Drug: Cimetidine plus CHF5993 pMDI

First Posted Date: 2014-11-10

Last Posted Date: 2021-10-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 25

Registration Number: NCT02287272

Locations: 🇧🇪
Life Science Services SGS Belgium NV, Antwerp, Belgium

Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF 5259
Drug: Placebo

First Posted Date: 2014-07-14

Last Posted Date: 2021-10-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 100

Registration Number: NCT02189577

Locations: 🇩🇪
Site 2020 - Pulmonary Research Institute at Hospital Grosshansdorf, Großhansdorf, Germany
🇧🇬
Chiesi Clinical Trial Site 1015, Sofia, Bulgaria
🇧🇬
Chiesi Clinical Trial Site 1013, Troyan, Bulgaria

and more 26 locations

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
Drug: Placebo
Drug: Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg

First Posted Date: 2014-05-28

Last Posted Date: 2017-03-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 60

Registration Number: NCT02148120

Locations: 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧
Hammersmith Medicines Research, London, United Kingdom
🇬🇧
Respiratory Clinical Trials, Hearth Lung Centre, London, United Kingdom

Triple in Asthma Dose Finding

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: CHF 5259 plus Foster 100/6 µg
Drug: Foster 100/6 µg

First Posted Date: 2014-05-01

Last Posted Date: 2021-04-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 211

Registration Number: NCT02127866

Locations: 🇧🇬
Chiesi Clinical Trial Site 0103, Stara Zagora, Bulgaria
🇧🇬
Chiesi Clinical Trial Site 0106, Sevlievo, Bulgaria
🇩🇪
Chiesi Clinical Trial Site 0208, Berlin, Germany

and more 41 locations

AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)

Completed

Conditions: Asthma

First Posted Date: 2014-04-25

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 872

Registration Number: NCT02123667

Locations: 🇧🇷
Prof. Dr. Alberto Cukier, São Paulo, Brazil
🇺🇸
Chiesi Clinical Trial Site #0503, Denver, Colorado, United States
🇺🇸
Chiesi Clinical Trial Site #0502, Durham, North Carolina, United States

and more 23 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy